Mayank And Lili Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 2.51 M
- Company Age 32 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -18.98%
- Profit Growth -6416.58%
- Ebitda -347.39%
- Net Worth -34.31%
- Total Assets 5.76%
About Mayank And Lili Pharma
Mayank And Lili Pharma Private Limited (MALPPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 January 1993 and has a history of 32 years and one month. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 2.51 M, as per Ministry of Corporate Affairs (MCA) records.
Mayankkumar Shah and Atulkumar Shah serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231GJ1993PTC018778
- Company No.
018778
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jan 1993
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
What products or services does Mayank And Lili Pharma Private Limited offer?
Mayank And Lili Pharma Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Protein Powder, Flavours & Aromatics, Dry Powder Flavours, Fitness Supplements, Ayurvedic,Herbal Products & Medicine, Diabetic Herbal Medicine.
Who are the key members and board of directors at Mayank And Lili Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mayankkumar Shah  | Director | 05-Jan-1993 | Current |
| Atulkumar Shah | Director | 05-Jan-1993 | Current |
Financial Performance of Mayank And Lili Pharma.
Mayank And Lili Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 18.98% decrease. The company also saw a substantial fall in profitability, with a 6416.58% decrease in profit. The company's net worth observed a substantial decline by a decrease of 34.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mayank And Lili Pharma?
In 2017, Mayank And Lili Pharma had a promoter holding of 24.78% and a public holding of 75.22%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mayank And Lili Pharma?
Unlock and access historical data on people associated with Mayank And Lili Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mayank And Lili Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mayank And Lili Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
